InMed Pharmaceuticals News

Press Releases

InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

September 22, 2020

InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update

September 8, 2020

InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020

September 2, 2020

InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755

July 7, 2020

InMed Announces Completion of Share Consolidation

June 30, 2020

InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System

June 24, 2020

InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

June 19, 2020

InMed Releases CBN Preclinical Results in Glaucoma

May 27, 2020

InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

May 19, 2020

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

May 14, 2020

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

May 14, 2020

InMed Files PCT Patent Application for Neuroprotection in Glaucoma

May 12, 2020

Notice of Telephone Scam Impersonating InMed

May 8, 2020

InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

May 8, 2020

InMed to Present at Canaccord Genuity’s 4th Annual Cannabis Conference

May 7, 2020

InMed and Almac Group Developing Improved Cannabinoid Production Methods

May 5, 2020

InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

April 30, 2020

InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

April 1, 2020

InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

March 24, 2020

InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak

March 20, 2020

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Press Releases

InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update

InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020

InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755

InMed Announces Completion of Share Consolidation

InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System

InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

InMed Releases CBN Preclinical Results in Glaucoma

InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

InMed Files PCT Patent Application for Neuroprotection in Glaucoma

Notice of Telephone Scam Impersonating InMed

InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

InMed to Present at Canaccord Genuity’s 4th Annual Cannabis Conference

InMed and Almac Group Developing Improved Cannabinoid Production Methods

InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive emails from InMed Pharmaceuticals